Autret E, Billard C, Bertrand P, Motte J, Pouplard F, Jonville A P
Department of Clinical Pharmacology, University of Tours, France.
J Pediatr. 1990 Sep;117(3):490-4. doi: 10.1016/s0022-3476(05)81104-7.
The aim of this study was to evaluate the efficacy and tolerance of intermittent oral administration of diazepam during hyperthermia for reducing the recurrence of febrile seizure: 185 children, between 8 months and 3 years of age, with a first febrile seizure and normal neurologic development, were randomly assigned in a double-blind fashion to receive orally administered diazepam (0.5 mg/kg, then 0.20 mg/kg, every 12 hours) or placebo, whenever the rectal temperature was more than 38 degrees C. The main criterion of efficacy was the seizure recurrence rate 1 year after the first seizure. The duration of the study was 3 years; eight different centers in France participated. There were 462 febrile episodes and 1000 days with prophylactic treatment. The recurrence rates did not differ between the diazepam group (16%) and the placebo (19.5%) group. The children with recurrent seizures were significantly younger at the time of the first seizure (17 +/- 6.9 months) than children without a recurrent seizure (21 +/- 8.5 months). In children with recurrent seizures, prophylactic treatment was correctly administered to only 1 of 15 children in the diazepam group and to 7 of 18 children in the placebo group. The following were the reasons for this poor cooperation: convulsion being the first manifestation of the fever (seven cases in each group), parents neglecting to give treatment (nine cases), and refusal to take treatment by two children. Side effects were similar in the two groups except for hyperactivity, which was more frequent in the diazepam (138 days) than in the placebo (34 days) group. Intermittent oral administration of diazepam at the onset of fever offered no advantage over placebo in preventing recurrence of seizure. This finding probably reflects a lack of efficacy of the intermittent method rather than of diazepam itself.
185名年龄在8个月至3岁之间、首次发生热性惊厥且神经发育正常的儿童,以双盲方式随机分配,每当直肠温度超过38摄氏度时,口服地西泮(0.5mg/kg,然后每12小时0.20mg/kg)或安慰剂。疗效的主要标准是首次惊厥后1年的惊厥复发率。研究持续时间为3年;法国的8个不同中心参与了研究。有462次发热发作和1000天的预防性治疗。地西泮组(16%)和安慰剂组(19.5%)的复发率没有差异。复发惊厥的儿童在首次惊厥时的年龄(17±6.9个月)明显小于未复发惊厥的儿童(21±8.5个月)。在复发惊厥的儿童中,地西泮组15名儿童中只有1名、安慰剂组18名儿童中有7名正确接受了预防性治疗。合作不佳的原因如下:惊厥是发热的首发表现(每组7例)、家长忽视给药(9例)以及两名儿童拒绝接受治疗。除多动外,两组的副作用相似,多动在使用地西泮的组中(138天)比在安慰剂组中(34天)更常见。发热开始时间歇性口服地西泮在预防惊厥复发方面并不比安慰剂更具优势。这一发现可能反映了间歇性给药方法缺乏疗效,而非地西泮本身缺乏疗效。